<DOC>
	<DOCNO>NCT02239731</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability efficacy FDX104 Antibiotic Foam prevention EGFRI skin toxicity cancer patient receive Cetuximab Panitumumab .</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Study Doxycycline Foam Prevention EGFRI Skin Toxicity Cancer Patients</brief_title>
	<detailed_description>This phase II multicenter , randomize , double blind , vehicle control clinical study evaluate safety , tolerability efficacy Doxycycline Foam 4 % prevention Epidermal Growth Factor Receptor Inhibition Skin Toxicity , Subjects Cancer Receiving Cetuximab Panitumumab weekly every 2 week basis . The study consist screen visit , treatment period patient treat topically face twice daily 5 week . A post-treatment follow visit ( 4 week end treatment ) , perform subject experience unresolved possibly-related related adverse event end treatment . Seven day randomization study drug initiation , subject start EGFRI treatment .</detailed_description>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>1 . Age 18 year old 2 . Subjects cancer receive Cetuximab Panitumumab weekly every 2 week basis . 3 . Scheduled start Cetuximab Panitumumab treatment ; 4 . Males nonpregnant , nonlactating female postmenopausal , naturally surgically sterile , negative subunit hCG pregnancy test immediately prior study entry . 5 . Able understand provide sign informed consent . 6 . Ability reliably apply topical FDX104 vehicle twice day appropriate part face 7 . Willingness minimize sun exposure 5 week randomization 8 . ECOG performance status 02 . 1 . Prior allergic reaction severe intolerance Doxcycycline and/or tetracycline . 2 . Prior allergic reaction severe intolerance soy coconut oil 3 . Cutaneous metastasis face might spread face . 4 . The presence active skin disease ( e.g. , eczema ) , tattoos problem application site , ( i.e. , locate face ) , investigator 's opinion , could confound evaluation rash make topical application unacceptable 5 . Hair face ( e.g beard ) would interfere application study drug evaluation . 6 . ANC &lt; 1,500/mm3 ( &lt; 1.5x109/L ) , Platelet count &lt; 100,000/mm3 ( &lt; 100x109/L ) 7 . Abnormal renal function : Serum creatinine &gt; 1.6 mg/dL 142umol/L ( SI unit ) calculate estimate creatinine clearance &lt; 40 ml/min1.73 m2 base Cockcroft Gault formula . 8 . Abnormal hepatic function : Serum Aspartate transaminase ( AST ) alanine tansaminase ( ALT ) &gt; 5 institutional upper limit normal ( ULN ) . Or Total billirubin &gt; 2 x institutional ULN &gt; 5 x institutional ULN document liver metastasis . 9 . Any clinically significant safety laboratory result , opinion Investigator , would place subject undue risk subject participate study 10 . Any clinically significant find physical examination , opinion Investigator , would place subject undue risk subject participate study 11 . Systemic lupus erythematosus 12 . Undergoing current biological treatment cancer prescribe EGFRI 13 . Treatment topical antibiotic , antiacne medication topical treatment face within 14 day prior treatment start . Use topical corticosteroid within 2 week prior baseline ; mild moderate topical steroid allow outside head neck area . The area exceed 10 % whole body surface area . In body fold , axillary inguinal region , mild topical steroid allow short term use ( â‰¤15 consecutive day ) . 14 . Treatment systemic antibiotic 7 day prior treatment start . 15 . Known suspected pregnancy , lactation plan pregnancy ( female ) 16 . Previous enrolment clinical trial involve investigational drug medical device within 30 day provision write informed consent study 17 . Subjects mentally physically unable comply aspect study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>EGFRI</keyword>
	<keyword>Epidermal Growth Factor Receptor Inhibition</keyword>
	<keyword>Skin toxicity</keyword>
	<keyword>Topical</keyword>
	<keyword>Doxycycline</keyword>
	<keyword>Foam</keyword>
	<keyword>Phase II</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>Vectibix</keyword>
	<keyword>Erbitux</keyword>
	<keyword>Rash</keyword>
</DOC>